Business Insider, April 6, 2017

"As stewards of the taxpayer, we need to know why CMS continues to pay for [Acthar] when Tricare and the nation's top insurance providers have severely restricted reimbursements for this drug," Sen. Tim Scott (R-SC) said in a letter to CMS.

 

Facebook icon
LinkedIn icon
Twitter icon